1. Pohanka E: Conversion to everolimus in maintence
patients-current clinical strategies. Nephrol Dial Transplant
2006; 21 (suppl 3): 24-29
2. Pascual J, Boletis IN, Campistol JM: Everolimus
(Certican) in renal transplantation: A review of clinical trial
data, curent usage, and future directions. Transplantation
Reviews 2006; 20: 1-18
3. Nahsan B: The role of certican (Everolimus, Rad) in the
Many pathways of chronic rejection. Transplantation
Proceedings 2001; 33: 3215-3220
4. Kasiske BL,Vazquez MA, Harmon WE, Brown RS,
Danovitch GM, Gaston RS, Roth D, Scandling JD,
Singer GG: For the American Society of Transplantation:
Recommendations for the outpatient surveillance of renal
transplant recipients. J Am Soc Nephrol 2000; 11(suppl
15):1-86
5. Reichel H, Zeier M, Ritz E: Proteinuria after renal
transplantation: Pathogenesis and management. Nephrol
Dial Transplant 2004; 19:301-305
6. Pascual M, Theeruvath T, Kawai T, Tolkoff-Rubin N,
Cosimi AB: Strategies to improve long-term outcomes
after renal transplantation. N Engl J Med 2002; 346:580-
590
7. Joosten SA, Sijpkens YWJ, Kooten CV, Paul LC: Chronic
renal allograft rejection: Pathophysiologic considerations.
Kidney Int 2005; 68: 1-13
8. Poul LC: Chronic allograft nephropathy: An update.
Kidney Int 1999; 56:783-793
9. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen
RD, Chapman JR: The natural history of chronic allograft
nephropathy. N Engl J Med 2003; 349(24):2326-2333
10. Allan JS, Madsen JC: Recent advances in the immunology
of chronic rejection. Curr Opin Nephrol Hypertens 2002;
11:315-321
11. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD,
Gores P, Gruessner R, Najarian JS: Risk factors for chronic
rejection in renal allograft recipients. Transplantation 1993;
55(4):752-757
12. Opelz G, Wujciak T, Ritz E: Association of chronic kidney
graft failre with recipient blood pressure. Collaborative
Transplant Study. Kidney Int 1998; 53:217-222
13. Krieger NR, Becker BN, Heisey DM, Voss BJ,
D’Alessandro AM, Becker YT, Odorico JS, Kalayoglu M,
Pirsch JD, Sollinger HW, Knenchtle SJ: Chronic allograft
nephropathy uniformly affects recipients of cadaveric,
nonidentical living-related, and living-unrelated graft.
Transplantation 2003; 75(10):1677-1682
14. Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S,
Steinberg S: Randomized trial of tacrolimus in combination
with sirolimus or mycophenolate mofetil in kidney
transplantation: Result at 6 months. Transplantation 2003;
75:1213-1220
15. Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik
S, Steinberg S, Prograf Study Group: A prospective,
randomized trial of tacrolimus in combination with sirolimus
or mycophenolate mofetil in kidney transplantation: Results
at 1 year. Transplantation 2005; 80(3):303-309
16. Johnson RWG, Kreis H, Oberbauer R, Brattstrom C,
Claesson K, Eris J: Sirolimus allows early closporine
withdrawal in renal transplantation resulting in improved
renal function and lower blood pressure. Transplantation
2001; 72:777-786
17. Bumbea V, Ribes D, Kamar N, Espositol L, Modesto A,
Guitard J, Nasou G, Durand D, Rostaing L: Outcome of
renal-transplant (RT) patients switched from calcineurin
inhibitors (CNIs) to sirolimus (SRL) for chronic allograft
dysfunction(CAD). Am J Transplant 2005; 5:463A(suppl
11;abstr 1202)
18. Diekmann F, Budde K, Oppenheimer F, Fritsche L,
Neumayer HH, Campistol JM: Predictors of success in
conversion from calcineurin inhibitor to sirolimus in
chronic allograft dysfunction. Am J Transplant 2004;
4:1869-1875
19. Wittmann S, Daniel C, Braun A, Vogelbacher R, Shimizu
F, Kawachi H, Hugo C. The mTOR inhibitor everolimus
attenuates the time course of chronic anti-Thy1 nephritis in
the rat. Nephron Exp Nephrol 2008; 108(2): 45-56
20. Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C:
The mTOR inhibitor everolimus induces proteinuria and
renal deterioration in the remnant kidney model in the rat.
Transplantation 2007; 84(11):1492-1499
21. Letavernier E, Legendre C: mTOR inhibitors-induced
proteinuria: Mechanisms, significance, and management.
Transplantation Reviews 2008; 22:125-130
22. Bertoni E, Bruschi M, Candiano G, Boccardi C, Citti L,
Mangraviti S, Rosso G, Larti A, Rosati A, Ghiggeri GM,
Salvadori M: Posttransplant proteinuria associated with
everolimus Transplant Proc 2009; 41(4):1216-1217
23. U.S. Renal Data Sistem: USRDS 2003 Annual data report:
atlas of end-stage renal disease in the United States 2003.
Bethesda: National Institutes of Health, National Institute
of Diabetes and Digestive and Kidney Disease, 2003;1-56
24. Briganti EM, Russ GR, McNeil JJ, Atkins RC,
Chadban SJ: Risk of renal allograft loss from recurrent
glomerulonephritis. N Engl J Med 2002; 347(2):103-109
25. Ponticelli C, Villa M, Cesana B, Montagnino G, Tarantino
A: 2002 Risk factors for late kidney allograft failure.
Kidney Int 2002; 62(5):1848-1854
Thank you for copying data from http://www.arastirmax.com
